Canopy Growth (CGC) vs Niagen Bioscience (NAGE)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Canopy Growth (CGC) has outperformed Niagen Bioscience (NAGE) over the past year, losing 44.7% versus a loss of 64.2%. Over five years, NAGE leads with a -58.2% price change compared with -99.4% for CGC. Canopy Growth is the larger company by market cap ($372.9 million vs $213.2 million), about 1.7 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CGC | NAGE |
|---|---|---|
| Share price | $0.83 | $2.70 |
| Market cap | $372.92M | $213.24M |
| 1-day change | -1.98% | +1.32% |
| YTD return | -25.72% | -58.18% |
| 1-year return | -44.65% | -64.20% |
| 5-year return | -99.37% | -58.18% |
| P/E ratio (TTM) | — | 14.18 |
| Forward P/E | — | 26.95 |
| EPS (TTM) | $-0.45 | $0.19 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.38 | $7.95 |
| 52-week low | $0.81 | $2.61 |
| Distance from 52-week high | -65.13% | -66.10% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +44.58% | +348.24% |
| Average volume | 2.77M | 585.61K |
| Shares outstanding | 423.04M | 79.13M |
| Employees | 1,128 | 117 |
| Sector | Health Care | Health Care |
| Industry | Medicinal Chemicals and Botanical Products | Medicinal Chemicals and Botanical Products |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CGC has outperformed NAGE by 19.5 percentage points over the past year.
About Canopy Growth
CGC stock →Canopy Growth Corporation, together with its subsidiaries, engages in the production, distribution, and sale of cannabis and cannabis-related products for medical and adult use in Canada, Germany, the United States, and internationally. The company operates through two segments, Cannabis and Storz & Bickel.
Health Care · Medicinal Chemicals and Botanical Products · 1,128 employees
About Niagen Bioscience
NAGE stock →Niagen Bioscience, Inc. operates as a bioscience company engages in developing healthy aging products.
Health Care · Medicinal Chemicals and Botanical Products · 117 employees
CGC vs NAGE FAQ
Which is bigger, Canopy Growth or Niagen Bioscience?
Canopy Growth (CGC) is larger, with a market capitalization of $372.92M compared with $213.24M for Niagen Bioscience (NAGE).
Which stock has performed better over the past year, CGC or NAGE?
CGC returned -44.65% over the past 12 months, compared with -64.20% for NAGE (price return, excluding dividends). Past performance does not predict future results.
Are Canopy Growth and Niagen Bioscience in the same industry?
Yes. Both are classified in the Medicinal Chemicals and Botanical Products industry within the Health Care sector.